Home › Medicines › Cephracap
বাংলায় দেখুন
Cephracap

Cephracap

Capsule

🧬 Cephradine 🏢 Euro Pharma Ltd.
Generic Name Cephradine
Manufacturer Euro Pharma Ltd.
Unit Price Unit Price: ৳ 15.00 (5 x 4: ৳ 300.00) Strip Price: ৳ 60.00

🔹 Indications

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Pharmacology

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Dosage & Administration

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Interaction

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Contraindications

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Side Effects

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Pregnancy & Lactation

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

🔹 Precautions & Warnings

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Cephracap:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Cephracap which is unaffected by this enzyme.

💡 Frequently Asked Questions

Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and o...
Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and o...
Cephracap is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and o...

User Reviews

⭐
No reviews yet!
Be the first to share your experience.

Write a Review

Alternative Medicines
(Same Generic)

Abac Powder for Suspension

Chemist Laboratories Ltd.

100 ml bottle: ৳ 95.00

Abac Capsule

Chemist Laboratories Ltd.

Unit Price: ৳ 15.00 (10 x 4: ৳ 600.00) Strip Price: ৳ 60.00

Abac Pediatric Drops

Chemist Laboratories Ltd.

15 ml bottle: ৳ 65.00

Acefra Powder for Suspension

Apollo Pharmaceutical Ltd.

100 ml bottle: ৳ 78.00

Acefra Capsule

Apollo Pharmaceutical Ltd.

Unit Price: ৳ 12.00 (20's pack: ৳ 240.00)

Adecef Capsule

Supreme Pharmaceutical Ltd.

Unit Price: ৳ 12.50 (24's pack: ৳ 300.00)

Adecef DS Powder for Suspension

Supreme Pharmaceutical Ltd.

100 ml bottle: ৳ 120.00

Adecef Powder for Suspension

Supreme Pharmaceutical Ltd.

100 ml bottle: ৳ 80.00

Ancef Capsule

UniMed UniHealth Pharmaceuticals Ltd.

Unit Price: ৳ 15.00 (5 x 4: ৳ 300.00) Strip Price: ৳ 60.00

Ancef Powder for Suspension

UniMed UniHealth Pharmaceuticals Ltd.

100 ml bottle: ৳ 95.00